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Abstract: 2,2,7-trimethylguanosine (TMG) binding proteins from human 
cells were purified through TMG-affinity columns. TMG synthesis was 
improved and the TMG obtained was shown to be similar to the TMG in the 
5' cap of the UsnRNAs. The eluates obtained with TMG-affinity 
chromatographies ,were very different from those isolated with m7G-affinity 
columns, thus suggesting that specific TMG-binding proteins were obtained. 
The fraction may be enriched with factors associated with import and/or 
hypermethylation of UsnRNPs. 
 
The trimethylguanosine (TMG) cap is the hallmark of the UsnRNAs (U 
small nuclear RNAs family) (1). Major UsnRNPs (U small nuclear 
ribonucleoproteins) U1, U2, U4/U6.U5 are essential spliceosomal factors. 
UsnRNPs are complexes consisting of UsnRNAs and a very characteristic set 
of polypeptides (2). Spliceosomal UsnRNPs contain common and specific 
polypeptides. The common polypeptides present in all the spliceosomal 
factors of human cells are B', B, D1, D2. D3, E, F and G. The common 
polypeptides not only form a common structure present in all the 
spliceosomal UsnRNPs, the so-called UsnRNPs core (2), but they also are 
important signals for the biogenesis of the UsnRNPs (3). With the sole 
exception of U6snRNA, which is capped with MeGTP, all the major UsnRNAs 
contain the TMG cap in human cells. Most UsnRNAs are synthesized by the 
RNA polymerase II and they are later modified in the nucleus with the 
addition of m7G cap (3). An active mechanism that recognizes the m7G cap 
exports these UsnRNAs to the cytoplasm, where biogenesis of the UsnRNPs 
takes place. In the cytoplasm, core (common) polypeptides are 
concentrated in three RNA-free complexes (1): slow sedimenting cores, 
containing B polypeptide sedimenting between 2-6S; middle sedimenting 
cores containing [D1, D2, (E, F, and G)2] sedimenting at 6S, and high 
sedimenting cores containing B, D3 and 69 kDa polypeptides. When 
spliceosomal UsnRNAs are exported to the cytoplasm, these RNA-free 
complexes associate with the UsnRNAs at the Sm-binding site [A(U)nG] to 
form the core particle that contains both the UsnRNAs and the core 
polypeptides B', B, D1, D2, D3, E, F and G (3). The 5' end of the UsnRNAs is 
then hypermethylated and the m7G cap changes to the m3G cap. The core 
polypeptides and the m3G cap form a bipartite nucleophilic signal that is 
recognized by a putative receptor (TMG-receptor) which mediates the 
import of the spliceosomal core particles from the cytoplasm to the nucleus 
(3). Recently, it has been described that both GTP-Ran and b importin might 
be some of the subunits of the TMG-receptor that imports TMG-capped 
UsnRNAs from the cytoplasm to the nucleus (4, 5). As b-importin and GTP-
Ran alone are not enough to import UsnRNPs, it has been suggested that 
other TMG-receptor subunits or TMG-adapters are necessary to reconstitute 
the complete receptor (5). This work is an intent to biochemically purify the 
TMG binding proteins with the purpose of further studying the presence of 
TMG-adapters. 
The TMG nucleoside here obtained is similar to the 5' end cap of the 
UsnRNAs. Our objective was to purify TMG binding proteins by a novel 
biochemical approach in order to better characterize factors that participate 
in the biogenesis of UsnRNPs. We prepared a TMG-affinity column and 
developed an easy purification method to prepare TMG binding proteins 
from cytoplasm. First, we had to synthesize high amounts of the non-
commercial TMG nucleoside, and to demonstrate that the obtained TMG 
nucleoside was essentially similar to the TMG cap of the UsnRNAs. TMG was 
synthesized from m2,2G by methylation of position 7 of the ring with 
dimethyl sulfate. TMG and m2,2G were easily separated and purified with a 
SP-Sephadex ion-exchange column. The procedure rendered a yield of 50% 
of the initial compound m2,2G, and NMR data confirmed that the substance 
obtained was TMG (data not shown). To demonstrate that the TMG here 
synthesized was similar to the TMG found at the 5' cap of the UsnRNPs, 
TMG or m2,2G nucleosides conjugated to the carrier KLH were used to 
immunize rabbits and mice. Mice were immunized with m2,2G-KLH 
conjugates for two reasons: 1) this nucleoside was used as immunization 
control, using a nucleoside different to TMG and 2) to study whether anti- 
m2,2G antibodies could recognize TMG. Four mice, M1, M2, M3 and M4, were 
immunized with m2,2G-KLH conjugate. Sera from all four mice showed low 
sera titers against TMG-BSA (not shown). Immunoprecipitation assays using 
nuclear extracts were performed with the sera from the four mice. To 
perform immunoprecipitation assays we used both mice and human nuclear 
extracts, as the TMG cap of the UsnRNPs is conserved during evolution. 
from yeast to human cells (1). Fig. 1A shows immunoprecipitation with sera 
from mice M1 and M2 (lanes 1 and 3, respectively) and a parallel inhibition 
assay by adding 10 mM TMG to the immunoprecipitation sample (lanes 2 
and 4, respectively). Lanes 1-4 in Fig 1A show that the mice sera did not 
recognize the TMG cap of the UsnRNPs from mice nuclear extracts. M3 and 
M4 mice rendered identical results, and pre-immune sera from Ml-M4 
showed background levels similar to those with the immunized Ml-M4 sera 
(not shown). M1 and M2 mice were re-immunized once with TMG-KLH 
conjugate, whereas that M3 and M4 were re-immunized once with m2,2G-
KLH conjugate, and blood was obtained from the four animals 7 days after 
the reimmunization. Sera from the two latter mice (M3 and M4) after re-
immunization did not immunoprecipitate UsnRNPs from mouse nuclear 
extract (not shown), but surprisingly, one injection of TMG-KLH to mice M1 
and M2 induced the synthesis of anti-TMG antibodies that recognized the 
cap of the UsnRNPs (see Fig. 1A. lanes 5 and 7, respectively). The reaction 
of these antibodies was specific, since it could be inhibited with free 10 mM 
TMG (Fig. 1A lanes 6 and 8, respectively). These results indicated that the 
methylation of the position of the guanosine ling is essential to obtain a 
good immune response to the TMG cap of the UsnRNPs. As the antibodies 
obtained against the m2,2G did not cross-react easily with TMG, we suggest 
that m2,2G and TMG nucleosides have important structural differences that 
are finely discriminated by the immune system of the animals. As the final 
goal of this study is to synthesize a column capable to purify TMG-binding 
proteins, the immunization results with m2,2G-conjugate indicated that TMG 
could not be replaced for m2,2G, and that the more successful results should 
be obtained with TMG-affinity columns than with m2,2G-affinity columns. 
 
 
FIG. 1 : Characterization of the synthesized TMG product. (A) 
Immunoprecipitation assays with sera from mice M1 and M2 immunized 
with m2,2G-KLH conjugate (lanes 1- 4) and sera of mice M1 and M2 re-
immunized with the TMG-KLH conjugate (5-8). Lanes 2,4, 6 and 8 were 
competed with 10 mM TMG nucleoside, and lanes 1,3,5 and 7 were not 
subjected to such competition. M1 serum was used in lanes 1.2.5 and 6; M2 
serum was used in lanes 3, 4, 7 and 8. The nuclear extract used was that 
obtained from EATC mouse cells (for lanes 1-9) and human nuclear extract 
for lane 10. Lane 10 was immunoprecipitated with the same sera that was 
used in lane 7 (from re-immunized M2). "m" indicates mouse. Lane 9 is the 
same amount of EATC nuclear extract used for each immunoprecipitation. 
The mobility of the human UsnRNAs is similar to that of the mUsnRNAs and 
it is therefore not shown in the figure. (B) Immunoprecipitation assays with 
pre-immune sera of M5 and M7 mice and sera from the M5-M8 mice 
immunized with TMG-KLH conjugate (lanes 1-10); lane 11 is the same 
nuclear extract used in each of these immunoprecipitations. The nuclear 
extract used was obtained from EATC mouse cells. Lane 1 and lane 6 were 
M5 and M7 pre-immune sera, respectively. Lanes 2 and 3, M5 serum; lanes 
4 and 5, M6 serum; lanes 7 and 8, M7 serum; lanes 9 and 10, M8 serum. 
Lanes 3, 5, 8 and 10 were immunoprecipitations competed with 10 mM TMG 
and lanes 2, 4, 7 and 9 were immunoprecipitations without TMG. "m" 
indicates mouse. (C) Immunoprecipitation assays with polyclonal rabbit sera 
from rabbit R331 (lanes 1-6) and rabbit R327 (lanes 7-12). Pre-immune 
sera were used in lanes 1, 4, 7 and 10. Lanes 2, 5, 8 and 11 were obtained 
from the rabbit immunized with TMG-KLH conjugate and lanes 3, 6, 9 and 
12 were experiments identical to those described in lanes 2, 5, 8 and 11, 
although carried out in presence of 10 mM TMG. In lanes 1-3 and 7-9, a 
HeLa nuclear extract was used as the source of antigen; and in lanes 4-6 
and 10-12, total yeast extract was used as the source of antigen. "h" means 
human and "y" means yeast. Fig. 1A and 1B are 10% polyacrylamide /6 M 
urea gels and Fig. 1C is a 6% polyacrylamide/6 M urea gel. All the gels were 
silver stained.  
 
We modified the synthetic procedure of the nucleoside conjugates 
that appeared in previous reports (6). Mainly, we observed that the 
conjugation of the TMG to the carrier protein improved in higher 
hydrophobic conditions (DMSO and ethanol) and increasing the temperature 
of oxidation and conjugation to 37 ºC. As this conjugation step would be the 
chosen method to covalently bind the nucleoside to a Sepharose matrix, it 
was important before preparing the TMG-affinity column to study whether 
the modification of the conjugation method affected the integrity of the TMG 
nucleoside. To better study this question, four mice (M5, M6, M7 and M8) 
and two rabbits were immunized with the improved TMG-KLH conjugate. 
Fig. 1B shows that all four mice showed immune response to the TMG cap 
of the mouse UsnRNPs, indicating that sera from the four animals 
immunoprecipitated UsnRNPs (see Fig. 1B lanes 2, 4, 7 and 9, respectively), 
and that the immune recognition was inhibited in presence of 10 mM TMG 
(Fig. 1B, lanes 3, 5, 8 and 10, respectively). Pre-immune sera from M5-M8 
mice showed background levels similar to those in the lanes competed with 
TMG (Fig. 1B shows the pre-immune sera from M5 and M7 mice, lanes 1 
and 6 respectively). Similar results were obtained with the sera from the 
two rabbits (R331 and R327) immunized with the improved TMG-KLH 
conjugate. Fig. 1C shows that sera from both rabbits recognized the TMG 
cap of the human UsnRNPs (lane 2 for R331 and lane 8 for R327), whereas 
the corresponding preimmune sera did not (lane 1 for R331 and lane 7 for 
R327). The UsnRNPs immunoprecipitation was inhibited in presence of 10 
mM TMG (lane 3 for R331 and lane 9 for R327). Similar results were 
obtained when UsnRNPs from yeast were immunoprecipitated with both 
sera (Fig. 1C, lanes 4-6 for R331, and immunoprecipitation was inhibited in 
presence of 10 mM TMG (lane 3 for R331 and lane 9 for R327). Similar 
results were obtained when UsnRNPs from yeast were immunoprecipitated 
with both sera (Fig. 1C, lanes 4-6 for R331, and lanes 10-12 for R327). All 
these results indicated that the improved method of conjugation did not 
affect the integrity of the TMG nucleoside bound to the protein carrier; thus, 
an anti-TMG cap antibody was easily obtained in the six animals immunized 
with the TMG-conjugate. These results indicated that the improved method 
of conjugation of the TMG to amine groups could be the method of choice to 
covalently bind the nucleoside TMG to amino-derivatived Sepharose 
TMG nucleoside was covalently bound to EAH-Sepharose 4 B using 
the improved conjugation method here described, i.e., ribose oxidation in 
presence of ethanol and DMSO at 37 ºC and conjugation to the amino-
deiivatived column at 37 ºC. In order to reduce binding of proteins that are 
recognizing guanosine or m7G and to reduce the presence of Sepharose-
binding proteins (non-specific binding) in the fractions eluted from the TMG-
affinity column, a pre-column with m7G covalently bound to Sepharose was 
prepared in a similar manner. 
Both columns had the same bed (around 4 ml) and were connected 
to each other in such a way that the flow-through of the m7G-affinity 
column was immediately applied to the second TMG-affinity column. The 
m7G-column has two finalities a) to deplete G- and m7G-binding proteins 
and b) to deplete proteins that could be interacting with the ribose moiety 
of the guanosine. The cytoplasmic extract from HeLa cells was different to 
the previously described S100 splicing fraction (7), as shown in the Material 
and Methods. After the sequential loading of the cytoplasmic extract, first to 
m7G-affinity column and second to the TMG-affinity column, each column 
was disconnected and separately washed. The proteins bound to the m7G-
affinity column or to the TMG-affinity column were specifically eluted by 
competition with free m7G or TMG, respectively, and collected in four 
different fractions (1 ml) that were analyzed in 15% polyacrylamide/ 0.1% 
SDS gels. The elution with the free nucleoside rendered native proteins. Fig. 
2 shows the proteins eluted from both columns: from the TMG-affinity 
column (lanes 2-5 corresponding to the first-to-last eluted fraction) and 
from the m7G-affinity column (lanes 6-9, corresponding to the first-to-last 
eluted fraction). The comparison of lanes 2-5 with lanes 6-9 in Fig. 2 
revealed that the pattern of m7G-binding proteins is clearly different from 
that of the TMG-binding proteins. The initial fractions eluted from the m7G-
affinity column (lanes 6-9) could contain the previously described CBP20 
and CBP80 (8), but they were not further characterized as these m7G-
binding proteins were not the purpose of this work. TMG-binding proteins 
showed a complex pattern and we marked 6 polypeptides (marked with a 
dark dot in Fig. 2 lanes 3 and 4) as the most prominent in the TMG eluate 
(Fig. 2, lanes 2-5). Their predicted molecular weights were, from top to 
bottom: 97 kDa; 52.6 kDa; 50.2 kDa; 33 kDa; 25.3 kDa; 19.1 kDa and 
17.9 kDa. These six polypeptides were observed in the four fractions eluted 
from the TMG-affinity column (compare lanes 2-5) and they are named as 
TMG-binding proteins. The protein pattern is quite different both from that 
of the m7G-binding proteins (compare lanes 2-5 with lanes 6-9 in Fig. 2), 
and from the protein pattern of the initial cytoplasmic fraction (not shown). 
In summary, we assume that the proteins described in Fig. 2, lanes 2-5 are 
TMG-binding proteins (specifically eluted from a TMG-affinity column) with a 
specific and native elution with TMG free nucleoside; besides, and these 
proteins are not eluted from the TMG affinity columns with m7G free 
nucleoside. Our preliminary results with Western blots indicated that b-
importin is present in TMG-binding fractions (D. Bahia, personal 
communication). This preliminary result is very interesting, since b-importin 
seems to be necessary for UsnRNPs import and it could be one of the 
subunits of the import complex (5). However, our results did not indicate 
whether b-importin binds directly to the TMG cap; therefore, b-importin 
could be present in TMG eluates by its association with a real TMG binding 
protein. Finally, we intend to use this fraction to study the different 
activities related with the TMG cap, such as UsnRNPs import, 
hypermethylation of the UsnRNA cap and other possible new activities not 
yet described. We are currently carrying out experiments to characterize 
these activities. 
 
 
FIG. 2: Purification of TMG-binding proteins. Lane 1, molecular weight 
markers (M) described to the left of the figure. A m7G-affinity column and a 
TMG-affinity column were sequentially loaded with cytoplasmic extract. 
Then, each column was separately washed and eluted respectively with free 
m7G nucleoside and free TMG nucleoside, respectively. Lanes 2-5 were 
protein fractions eluted from the TMG-affinity column by competition with 
free TMG nucleoside; lanes 6-9 were eluted from m7G-affinity column with 
free m7G nucleoside. Lanes 2-5 represent the four fractions from the elution 
profile, 2 being the first and 5 the last. Lanes 6-9 represent the four 
fractions from the elution profile, 6 being the first and 9 the last. The most 
prominent proteins in TMG eluate (lane 3 and 4) were marked with a dark 
dot, and the molecular weight of the marked proteins is, from top to 
bottom: 97 kDa; 52.6 kDa; 50.2 kDa; 33 kDa; 25.3 kDa; 19.1 kDa and 
17.9 kDa. The proteins were run in a 15% polyacrilamide/0.l% SDS gel and 
stained with Coomassie blue. 
 
 
EXPERIMENTAL SECTION 
 
Abbreviations used: TMG, N2, N2,7-trimethylguanosine; TEAB, Et3NHC03; 
EATC, Ehrlich ascites tumor cells; DMS, dimethyl sulfate; DMSO, dimethyl 
sulfoxide. 
 
Synthesis of N2, N2,7-trimethylguanosine (TMG, or m3G or m2,2,7G or 
2,2,7-trimethylguanosine).  
The TMG precursor was N2, N2-dimethylguanosine (m2,2G), which was 
synthesized as previously described 9. The synthesis of TMG from m2,2G was 
performed essentially as previously described with some modifications lo. In 
brief: 80 mg of m2,2G were dissolved in 1726 ml of dimethylacetamide 
(99%) and 54 ml of dimethyl sulfate (DMS). The methylation reaction was 
allowed to proceed for 12 h at room temperature. Then, 2 ml of TEAB pH 
8.3 (Et3NHC03) was added and loaded to a SP Sephadex G-25 (Pharmacia), 
at 4 ºC (the bed column was 29 ml, and the column size had a diameter of 
2.5 cm and a height of 6 cm) equilibrated with 5 mM TEAB pH 8.3. The 
column was washed with 5 mM TEAB pH 8.3 until the flow-through, which 
contained the m2,2G that had not converted to TMG, did not show any 
significant absorbance at 260 nm. TMG was eluted with 50 mM TEAB pH 8.3 
and was subjected to 3-4 cycles of lyophilization and subsequent dissolution 
in water, in order to remove the TEAB buffer. Normally the synthesis 
reaction rendered a yield of 50% of the initial compound m2,2G. NMR data 
confirmed that the compound obtained was m3G (data not shown). 
 
Synthesis of the TMG-HSA (human serum albumin) and TMG-KLH 
(keyhole limpet hernocyanin). 
The method previously reported by Erlanger and Beiser (6) was 
modified. Four mg of TMG was dissolved in 106 ml of ethanol and 69 ml of 
dimethyl sulfoxide (DMSO). Then 4 mg of NaIO4 in 200 ml of H20 was 
added to the initial TMG mixture, and the oxidation reaction was allowed to 
proceed for 90 minutes at 37 ºC in the dark. Then, 14 ml of 1 M ethylene 
glycol was added and the mixture was allowed to further react for 10 min at 
37 O C in the dark. Four mg of the carrier protein (HSA or KLH) dissolved in 
1 ml of 0.4 M NaHC03 pH 9.1 was added drop by drop. The mixture was 
adjusted to pH 9.1 with 1 M NaHC03 pH 9.1, and allowed to react for 2 h at 
room temperature in the dark. Then, 20 mg (powder) of tert-
butylamineborane was slowly added and allowed to react for 45 min at 4°C. 
The conjugation was centrifuged for 10 min at 12.000 g and then desalted 
with a PD-10 column (Pharmacia). m2,2G-HSA and m2,2G-KLH conjugates 
were prepared in a similar way to that described for the TMG conjugate. 
 
Nuclear and cytoplasmic extracts from human cells. 
Nuclear extracts from HeLa cells, (cells provided by 4C Company, 
Computer Cell Culture Center S.A., Mons, Belgium) were obtained following 
the method of Dignam et al. (7). Cytoplasmic extracts were also obtained 
by the method of Dignam et al. (7): after hypotonic treatment of the HeLa 
cells in buffer A, 10 mM HEPES-KOH pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 
mM DTT, and disruption in a homogenizer (Dounce B) the broken cells were 
centrifuged for 10 min at 100 g. The supernatant (S1) was then carefully 
removed with a pipette. Then, the nuclear pellet was centrifuged again at 
25,000 g for 20 min, this second supernatant (S2) was carefully removed 
from the pellet, and S2 was mixed with S1. The cytoplasmic extract used in 
this work corresponded to the mixture of S1 and S2 supernatants. The 
cytoplasmic extract was stored at -80 ºC until needed. The nuclear extracts 
from EATC (Ehrlich ascites tumor cells) mouse cells were prepared as 
previously described (11). 
 
Total yeast extracts. 
Total yeast extract was obtained from strain EJ101 as described 
elsewhere (12). 
 
Immunization of mice and rabbits with TMG-KLH or m2P2G-KLH 
conjugates. 
Two rabbits, R327 and R331, were subcutaneously immunized with 2 
mg of TMG-KLH conjugate (in 1 ml PBS) mixed with 1 ml of either complete 
or incomplete Freund adjuvant. Rabbits were immunized with complete 
Freund adjuvant on day 0, and with incomplete Freund adjuvant on days 
21, 35 and 42. On day 49 blood was taken from the animal's ears. Sera was 
obtained by centrifugation of the blood and their titer assayed by ELISA, 
which wells contained the TMG-HSA conjugate. Four mice were immunized 
with m2,2G-KLH conjugate (M1-M4) and four more mice with TMG-KLH 
conjugate (M5-M8) as following: 400 ml of nucleoside-conjugate (the final 
quantity injected was 400 mg) in PBS mixed with complete Freund adjuvant 
(1:1, v/v) was intraperitoneally injected to each mice on day 0, and the 
animals were then immunized again on days 14 and 21. On day 28 blood 
was taken from the tail vein. Sera was obtained by centrifugation of the 
blood and their titer assayed by ELISA, which wells contained the 
nucleoside-HAS conjugate. The four animals injected with the m2,2G-KLH 
conjugate were injected once more on day 35; two with TMG-KLH conjugate 
(M1 and M2) and the other two with m2,2G-KLH conjugate (M3 and M4). On 
day 42, blood was taken from these four animals. All the experiments 
described here were performed with mouse sera from 28 days, with the 
exception of the mice M1-M4, that were re-immunized and whose sera from 
42 days was also assayed. 
 
Preparation of TMG-Sepharose and m7G-Sepharose affinity columns. 
Two affinity columns were prepared: one that contained the 
nucleoside m7G covalently bound to Sepharose and a second one with the 
nucleoside TMG covalently bound to Sepharose. Both columns were 
obtained using the same procedure: 250 mg of each nucleoside was 
dissolved in 6.6 ml of ethanol and 4.3 ml of DMSO. Then, 250 mg of NaIO4 
in 12.5 ml of H20 was added to the TMG initial mixture, and the oxidation 
reaction was allowed to proceed for 90 min at 37 ºC in the dark. Then, 875 
ml of 1 M ethylene glycol was added and the mixture was allowed to react 
for another 10 min at 37 ºC in the dark. NaCl (0.49 g) and NaHC03 (0.28 g) 
were next added to the nucleoside oxidation reaction. Meanwhile, 3 ml EAH-
Sepharose 4 B (Pharmacia) were washed four times with 50 ml of 0.5 M 
NaCl; five times with 50 ml of 0.5 M NaCl/ 0.2 M NaHCO3 pH 9.1 and finally 
resuspended in 3 ml of 0.5 M NaCl/ 0.2 M NaHC03 pH 9.1. The oxidized 
nucleoside solution was mixed (drop by drop) with the resuspended resin, 
and the binding was allowed to proceed by rotation for 3 h at room 
temperature in the dark. Then, 1.25 g (powder) of tert-butylamineborane 
was slowly added and allowed to react by rotation for 1h at 4°C. The resin 
was washed with 50 ml of 0.5 M NaCl and 50 ml of H20 and the column was 
equilibrated with TMG-buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 150 mM 
NaCl, 0.5 mM DTT, 0.5 mM PMSF and 5% glycerol). Both resins were 
mounted inside two 2.5 cm (diameter) columns. The TMG-Sepharose and 
m7G-Sepharose affinity columns were stored in presence of 0.02% NaN3 / 
TMG buffer. 
 
Purification of TMG binding proteins through m7G-Sepharose and 
TMG-Sepharose affinity columns. 
The m7G-Sepharose column was connected to the TMG-Sepharose 
column. Before loading, cytoplasmic extract (250 ml) was dialyzed against 
TMG-buffer. The dialyzed fraction was first loaded on the m7G-Sepharose 
column, and the flow through of this column was loaded on the TMG-column 
overnight. Then the two columns were disconnected one from the other and 
each column was washed separately with 10 bed-volumes of TMG-buffer. 
The m7G-Sepharose column was eluted with 10 mM m7G in the TMG-buffer 
and TMG-column was eluted with 10 mM m3G in TMG-buffer; the latter 
fraction contained the TMG binding proteins. 
 
Immunoprecipitation of nuclear extracts. 
Immunoprecipitation of the UsnRNPs from nuclear extracts with anti-
TMG was essentially performed as previously described (13). Protein A or 
Protein G was used with sera from rabbit or mice, respectively. 
 
Protein and RNA gels. Protein and RNA gels staining. 
Protein and RNA gels were performed as previously described (11). 
Protein gels were stained with Coomassie Blue and RNA gels were stained 
with silver, as described (11). 
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